Exact Sciences Corporation

Exact Sciences Corporation is a leading American molecular diagnostics company headquartered in Madison, Wisconsin. Established in 1995, the company is dedicated to eradicating cancer by preventing it, detecting it earlier, and guiding personalized treatment.

The company's flagship product, Cologuard®, is a non-invasive stool-based DNA screening test approved by the FDA in 2014. It detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer, offering a convenient alternative to traditional colonoscopy.

Product Portfolio

Exact Sciences offers a comprehensive portfolio of tests and services across the cancer continuum including:

• Oncotype DX®: A genomic test assessing risk of recurrence in early-stage breast cancer patients, aiding personalized treatment decisions.
• OncoExTra®: A solid tumor profiling test guiding therapy selection for advanced, metastatic, refractory, relapsed, or recurrent cancers.
• Oncoguard® Liver: Blood-based screening test for liver cancer, especially in individuals with cirrhosis or hepatitis B.
• Riskguard®: Detects genetic mutations to assess hereditary cancer risk through blood and saliva samples.

Locations

Exact Sciences operates globally, with numerous offices and laboratories.

United States locations include:

• Madison, Wisconsin (headquarters)
• Cambridge, Massachusetts
• Phoenix, Arizona
• Redwood City, California
• San Diego, California
• Salt Lake City, Utah
• Rochester, Minnesota
• Marshfield, Wisconsin
• Washington, D.C.

International locations include:

• Baar (Zug), Switzerland
• London, England
• Milan, Italy
• Munich, Germany
• Oxford, England
• Paris, France
• Tokyo, Japan
• Trier, Germany
• Warsaw, Poland

Company Size

With a team of over 6,500 employees, Exact Sciences is committed to advancing cancer diagnostics and treatment. The company strives to provide patients and healthcare providers with innovative, accurate, and accessible solutions.